VivoSim Labs (NASDAQ:VIVS) Issues Quarterly Earnings Results

VivoSim Labs (NASDAQ:VIVS) announced its earnings results on Wednesday. The company reported ($1.03) earnings per share for the quarter, FiscalAI reports. VivoSim Labs had a negative net margin of 1,413.57% and a negative return on equity of 28.83%. The business had revenue of $0.03 million for the quarter.

VivoSim Labs Stock Performance

Shares of VIVS stock opened at $1.91 on Friday. VivoSim Labs has a 1 year low of $1.41 and a 1 year high of $21.96. The business’s fifty day moving average is $2.07 and its 200-day moving average is $2.37. The stock has a market cap of $4.99 million, a PE ratio of -0.43 and a beta of 1.21.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, VivoSim Labs currently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP purchased a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs at the end of the most recent quarter. 8.23% of the stock is owned by institutional investors and hedge funds.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.